Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6548
    +0.0025 (+0.39%)
     

  • OIL

    84.06
    +0.49 (+0.59%)
     

  • GOLD

    2,357.40
    +14.90 (+0.64%)
     

  • Bitcoin AUD

    98,169.40
    +345.20 (+0.35%)
     

  • CMC Crypto 200

    1,388.57
    -7.96 (-0.57%)
     

  • AUD/EUR

    0.6099
    +0.0026 (+0.43%)
     

  • AUD/NZD

    1.0982
    +0.0024 (+0.22%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,123.82
    +44.96 (+0.56%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,028.75
    +111.47 (+0.62%)
     

  • Hang Seng

    17,663.26
    +378.72 (+2.19%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

Myriad Genetics, Inc.
·1-min read
Myriad Genetics, Inc.
Myriad Genetics, Inc.

SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and CEO, will participate in the 44th Annual Goldman Sachs Global Healthcare Conference with a fireside chat on Tuesday, June 13, 2023 at 2:00 p.m. PT.

A replay of the fireside chat will be available on the investor relations section of Myriad’s website at www.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Media Contact:

Investor Contact:

Glenn Farrell

Matt Scalo

(385) 318-3718

(801) 584-3532

PR@myriad.com

IR@myriad.com